JPMorgan raised the firm’s price target on Vera Therapeutics (VERA) to $99 from $52 and keeps an Overweight rating on the shares. The firm is updating its model for Vera following multiple competitive updates for Voyxact (sibeprenlimab) in IgA Nephropathy, the analyst tells investors in a research note. With the evolving market dynamics, particularly total addressable market considerations, the firm sees the product as potentially strategically attractive, JPMorgan added.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on VERA:
- Strategic Positioning and Market Opportunities Favor Vera Therapeutics: A Buy Recommendation
- Vera Therapeutics rises 19.2%
- These 3 Stocks Have Triple-Digit Upside Potential, Say Five-Star Analysts – 11/26/2025
- Vera Therapeutics Appoints James R. Meyers to Board
- Optimistic Buy Rating for Vera Therapeutics Driven by Atacicept’s Commercial Potential and Favorable Valuation